Clinical Trial Update: Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating pembrolizumab after radiation therapy in patients with malignant pleural mesothelioma. Results were posted on 2025-11-13.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Pleural Malignant Mesothelioma | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-11-13